Online:
Visits:
Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

2017 Forecast – Non Small-Cell Lung Cancer Global Market News, Industry Size, Share, Analysis and Research to 2022

Tuesday, March 7, 2017 5:27
% of readers think this story is Fact. Add your two cents.

(Before It's News)

New report on Global Non Small-Cell Lung Cancer market is segmented into types, therapeutics and geography. Based on the types, global non small-cell lung cancer market is further segmented into squamous cell carcinoma, adenocarcinoma, large cell carcinoma and others. The market is segmented on the basis of therapeutics into chemotherapy, targeted therapy, surgery, radiotherapy and pipeline drugs. Key players profiled in the market are Pfizer, Roche, AstraZeneca, Eli Lily, GlaxoSmithKline, Novartis AG, Merck & Co., and Agennix AG. Collaboration, product launch and acquisition are some of the strategies adopted by key players in the non-small cell lung cancer market. For example, on April 21, 2015, Pfizer received the USFDA approval for potential treatment of patients with ROS1-positive non-small cell lung cancer. On November 21, 2014, GSK collaborated with Clovis oncology to design clinical trials for the evaluation of new combination therapy used in NSCLC treatments.

Get Free Sample Report Of Non Small-Cell Lung Cancer Market @ http://www.marketresearchstore.com/report/world-non-small-cell-lung-cancer-market-opportunities-70997#RequestSample

Non-small cell Lung cancer is the malignant tissue formation in the lung, usually in the cell lining air passage, which is characterized by abnormal cell growth in lung tissue. Globally, lung cancer is one of the leading causes of death since the past several decades. According to the American lung association, the number of deaths due to lung cancer has increased ~3.5% from ~152,156 cases in 1999 to ~157,499 in 2012. Furthermore, it is estimated that 158,040 Americans are would die due to lung cancer by 2015. According to the American Society of cancer, non small-cell lung cancer accounts for ~85% to 90% of overall lung cancer cases and the trend is expected to grow with the same momentum. Thus, a large patient base of non small-cell lung cancer depicts the unmet need for diagnosis and treatment. It has been observed that non small-cell lung cancer is the most prevalent type of lung cancer commonly caused due to active and passive smoking.

Do Inquiry To Buy Report Of Non Small-Cell Lung Cancer Market @ http://www.marketresearchstore.com/report/world-non-small-cell-lung-cancer-market-opportunities-70997#InquiryForBuying

Global non small-cell lung cancer market- by Type

  • Squamous cell (epidermoid) carcinoma
  • Adenocarcinoma
  • Large cell (undifferentiated) carcinoma
  • Other

Global non small-cell lung cancer market- by Therapy

  • Chemotherapy
  • Targeted therapy
  • Surgery
  • Radiotherapy
  • Laser therapy
  • Photodynamic therapy (PDT)
  • Others

 Global non small-cell lung cancer market- by Geography

  • North America
  • Europe
  • Asia-Pacific
  • LAMEA
  • SIMILAR MARKET STUDIE

Contact Us:

Joel John
3422 SW 15 Street, Suit #8138,
Deerfield Beach, Florida 33442, USA
USA Tel: +1-386-310-3803
GMT Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651
Email: [email protected] 
Web: http://www.marketresearchstore.com/

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories
 

Featured

 

Top Global

 

Top Alternative

 

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.